Logo for AnaptysBio Inc

AnaptysBio Investor Relations Material

Latest events

Logo for AnaptysBio Inc

PD-1 Agonist Rosnilimab R&D Event

AnaptysBio
Logo for AnaptysBio

Q1 2024

9 May, 2024
Logo for AnaptysBio

Q4 2023

11 Mar, 2024
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from AnaptysBio Inc

Access all reports
AnaptysBio Inc is a clinical-stage biotechnology company. It focuses on developing immunology therapeutics aimed at autoimmune and inflammatory diseases. The company's product pipeline includes several key antibody candidates like Imsidolimab, an anti-IL-36 receptor antibody for treating generalized pustular psoriasis, currently in Phase 3 trials. Another significant product is Rosnilimab, an anti-PD-1 agonist antibody designed to address T-cell driven inflammatory diseases. Additionally, ANB032, an anti-BTLA modulator antibody, is being developed for various human inflammatory diseases linked to immune cell dysregulation. The company is headquartered in San Diego, California, and its shares are listed on the Nasdaq.